Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT07101939

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

Led by Actimed Therapeutics Ltd · Updated on 2026-02-17

120

Participants Needed

7

Research Sites

88 weeks

Total Duration

On this page

Sponsors

A

Actimed Therapeutics Ltd

Lead Sponsor

S

SCIRENT Clinical Research and Science d.o.o.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).

CONDITIONS

Official Title

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Eligible for treatment with semaglutide
  • Have a body mass index (BMI) of 30.0 kg/m² or higher
Not Eligible

You will not qualify if you...

  • Diagnosis of type 2 diabetes mellitus with any of the following in the past 90 days: use of GLP-1RA (including semaglutide), hypoglycemic event, weight loss greater than 5 kg, or HBA1C over 10.0%
  • Cardiovascular event within the previous 6 months
  • Uncontrolled hypertension
  • Known congestive heart failure or angina during the past year
  • Known severe chronic obstructive pulmonary disease (COPD)
  • Use of beta blockers or contraindications to beta blockers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje'

Belgrade, Serbia

Actively Recruiting

2

Clinical Hospital Center Bezanijska kosa

Belgrade, Serbia

Actively Recruiting

3

University Clinical Center of Serbia

Belgrade, Serbia

Actively Recruiting

4

University Clinical Center Kragujevac

Kragujevac, Serbia

Actively Recruiting

5

Klinika Za Endocrinologiju, Dijabetes I Bolesti Metabolizma

Niš, Serbia

Actively Recruiting

6

University Clinical Center of Vojvodina

Novi Sad, Serbia

Actively Recruiting

7

Opsta bolnica Pancevo

Pančevo, Serbia

Actively Recruiting

Loading map...

Research Team

F

Fabio Dorigotti, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) | DecenTrialz